- Home
- PCF vs CGEN Comparison
PCF vs CGEN Comparison
Compare PCF & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCF
- CGEN
- Stock Information
- Founded
- PCF 1987
- CGEN 1993
- Country
- PCF United States
- CGEN Israel
- Employees
- PCF N/A
- CGEN N/A
- Industry
- PCF Trusts Except Educational Religious and Charitable
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCF Finance
- CGEN Health Care
- Exchange
- PCF Nasdaq
- CGEN Nasdaq
- Market Cap
- PCF 116.8M
- CGEN 125.3M
- IPO Year
- PCF N/A
- CGEN 2000
- Fundamental
- Price
- PCF $6.20
- CGEN $1.57
- Analyst Decision
- PCF
- CGEN
- Analyst Count
- PCF 0
- CGEN 0
- Target Price
- PCF N/A
- CGEN N/A
- AVG Volume (30 Days)
- PCF 74.8K
- CGEN 286.4K
- Earning Date
- PCF 01-01-0001
- CGEN 11-10-2025
- Dividend Yield
- PCF 10.90%
- CGEN N/A
- EPS Growth
- PCF N/A
- CGEN N/A
- EPS
- PCF N/A
- CGEN N/A
- Revenue
- PCF N/A
- CGEN $6,903,000.00
- Revenue This Year
- PCF N/A
- CGEN N/A
- Revenue Next Year
- PCF N/A
- CGEN $208.08
- P/E Ratio
- PCF N/A
- CGEN N/A
- Revenue Growth
- PCF N/A
- CGEN N/A
- 52 Week Low
- PCF $5.71
- CGEN $1.13
- 52 Week High
- PCF $6.96
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- PCF 46.15
- CGEN 45.22
- Support Level
- PCF $5.92
- CGEN $1.51
- Resistance Level
- PCF $6.21
- CGEN $1.66
- Average True Range (ATR)
- PCF 0.06
- CGEN 0.10
- MACD
- PCF -0.01
- CGEN -0.01
- Stochastic Oscillator
- PCF 70.51
- CGEN 25.00
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.